49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 10 of 25 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05666336 (ClinicalTrials.gov) | December 31, 2022 | 8/12/2022 | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients | Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of ... | Systemic Lupus Erythematosus | Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: Tacrolimus Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cy ... | Fen Li | NULL | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 4 | NULL |
2 | ChiCTR2100048796 | 2021-07-15 | 2021-07-16 | A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective non-randomized controlled study of integrated traditional Chinese and western medicine ... | A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective cohort study of integrated traditional Chinese and western medicine for moderately act ... | Systemic lupus erythematosus | Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide); Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome ... | Zhejiang Chinese Medical University | NULL | Pending | 18 | 65 | Female | Experimental group:264;Control Group:264; | N/A | China |
3 | ITMCTR2100005063 | 2021-07-15 | 2021-07-16 | A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective non-randomized controlled study of integrated traditional Chinese and western medicine ... | A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective cohort study of integrated traditional Chinese and western medicine for moderately act ... | Systemic lupus erythematosus | Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide); Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome ... | Zhejiang Chinese Medical University | NULL | Pending | 18 | 65 | Female | Experimental group:264;Control Group:264; | N/A | China |
4 | ChiCTR2200055471 | 2021-01-01 | 2022-01-10 | Efficacy and safety of low-dose CTX combined with belimumab based on B/T cell balance in the treatment of moderate to severe systemic lupus erythematosus: a medical record-based study Efficacy and safety of low-dose CTX combined with belimumab based on B/T cell balance in the treatme ... | Efficacy and safety of low-dose CTX combined with belimumab based on B/T cell balance in the treatment of moderate to severe systemic lupus erythematosus Efficacy and safety of low-dose CTX combined with belimumab based on B/T cell balance in the treatme ... | Systemic Lupus Erythematosus (SLE) | belimumab group:Low-dose cyclophosphamide combined with belimumab;cyclophosphamide group:Standard dose cyclophosphamide; belimumabgroup:Low-dose cyclophosphamidecombined with belimumab;cyclophosphamidegroup:Standard dose ... | The Second Hospital of Shanxi Medical University | NULL | Recruiting | 18 | 80 | Both | belimumab group:40;cyclophosphamide group:42; | China | |
5 | NCT03492255 (ClinicalTrials.gov) | April 12, 2018 | 16/3/2018 | CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid | CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid | Systemic Lupus Erythematosus (SLE) | Drug: Cyclophosphamide;Drug: Methylprednisolone;Drug: Prednisone;Drug: Mycophenolate Mofetil | University of Sao Paulo General Hospital | Fundação de Amparo à Pesquisa do Estado de São Paulo | Terminated | 18 Years | N/A | All | 49 | N/A | Brazil |
6 | NCT03030976 (ClinicalTrials.gov) | March 2017 | 22/1/2017 | A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) | An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE) An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19- ... | Systemic Lupus Erythematosus (SLE) | Drug: cyclophosphamide;Drug: anti-CD19-CAR-T cells | Shanghai GeneChem Co., Ltd. | RenJi Hospital | Recruiting | 18 Years | 69 Years | All | 5 | Phase 1 | China |
7 | NCT02080195 (ClinicalTrials.gov) | September 13, 2016 | 28/2/2014 | Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythe ... | A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen ( ... | Lupus Erythematosus;Graft-versus-host Disease | Drug: Cyclophosphamide;Drug: Fludarabine;Drug: Tacrolimus;Drug: Mycophenolate Mofetil;Drug: Rabbit antithymocyte globulin;Radiation: Total body irradiation;Biological: Allogeneic bone marrow transplant Drug: Cyclophosphamide;Drug: Fludarabine;Drug: Tacrolimus;Drug: MycophenolateMofetil;Drug: Rabbitant ... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Maryland Stem Cell Research Fund | Terminated | 18 Years | 75 Years | All | 1 | Phase 1/Phase 2 | United States |
8 | ChiCTR-ONC-15007547 | 2015-12-05 | 2015-12-04 | Clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus: a multicenter prospective cohort study Clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus: a multic ... | Study of the clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus Study of the clinical theraputic effect of traditional Chinese medicine on systemic lupus erythemato ... | systemic lupus erythematosus | The combination of Chinese and western group:Traditional Chinese medicine combined western medicine;Treating by Western Medicine group:Treating by Western medicine (sugar cortical hormone, hydroxychloroquine, and methotrexate, azathioprine, or cyclophosphamide); The combination of Chinese and western group:Traditional Chinese medicine combined western medicine; ... | Zhejiang Chinese Medical University | NULL | Recruiting | 18 | 60 | Both | The combination of Chinese and western group:264;Treating by Western Medicine group:264; | China | |
9 | NCT02444728 (ClinicalTrials.gov) | July 2015 | 12/5/2015 | Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE | Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus Cyclophosphamideand Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupu ... | Thrombocytopenia | Drug: Hydroxychloroquine;Drug: Cyclophosphamide;Drug: Azathioprine;Drug: Methylprednisolone | Chinese SLE Treatment And Research Group | Peking Union Medical College Hospital | Recruiting | 18 Years | 70 Years | All | 220 | Phase 3 | China |
10 | NCT01689350 (ClinicalTrials.gov) | October 2012 | 17/9/2012 | A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment | Prospective Study Based on Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment Prospective Study Based on Genetic Polymorphisms Related to Individual Variations of Side Effects of ... | Systemic Lupus Erythematosus | Genetic: Genotype Detection | Sun Yat-sen University | First Affiliated Hospital, Sun Yat-Sen University | Completed | 12 Years | 60 Years | All | 92 | N/A | China |